文献速递癫痫

加奈索酮治疗CDKL5缺陷障碍患者的安全性和有效性:随机、安慰剂对照3期试验双盲阶段结果

Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Neurol · 2022-01-01

这项在8个国家39个门诊进行的随机、安慰剂对照3期试验双盲阶段纳入101例2-21岁CDKL5缺陷障碍患者,加奈索酮组50例、安慰剂组51例,主要终点为28天主要运动性发作频率中位数百分比变化。加奈索酮组为-30.7%,安慰剂组为-6.9%(p=0.0036),加奈索酮较安慰剂显著降低发作频率,且总体耐受性良好。

要点

  • 加奈索酮组28天主要运动性发作频率中位数变化-30.7%,安慰剂组-6.9%(p=0.0036)。
  • 加奈索酮组治疗中出现不良事件43/50例(86%),安慰剂组45/51例(88%)。
  • 加奈索酮组严重不良事件6/50例(12%),安慰剂组5/51例(10%),双盲阶段无死亡。

核心结论

  • 加奈索酮较安慰剂显著降低CDKL5缺陷障碍相关发作频率,且总体耐受性良好。
  • 作者认为这是其所知首个在CDKL5缺陷障碍中开展的对照试验,结果提示加奈索酮可能具有治疗获益。
  • 长期治疗正在该试验正在进行的开放标签扩展阶段中评估。

研究设计与样本

  • 随机、安慰剂对照3期试验双盲阶段,在8个国家(澳大利亚、法国、以色列、意大利、波兰、俄罗斯、英国和美国)的39个门诊进行。
  • 纳入2-21岁、携带致病或可能致病CDKL5变异、且8周历史期每个4周期间至少16次主要运动性发作的患者。
  • 经过6周前瞻性基线期后,按1:1随机分配接受肠内辅助加奈索酮或匹配肠内辅助安慰剂,治疗17周。
  • 加奈索酮最大剂量为体重≤28 kg者63 mg/kg/日或体重>28 kg者1800 mg/日。
  • 共筛查114例,随机分配101例(中位年龄6岁,IQR 3-10),加奈索酮组50例、安慰剂组51例。

主要发现

  • 加奈索酮组28天主要运动性发作频率中位数百分比变化为-30.7%(IQR -49.5至-1.9),安慰剂组为-6.9%(IQR -24.1至39.7),p=0.0036。
  • 加奈索酮相对安慰剂的中位反应差异Hodges-Lehmann估计值为-27.1%(95% CI -47.9至-9.6)。
  • 治疗中出现不良事件:加奈索酮组43/50例(86%),安慰剂组45/51例(88%)。
  • 嗜睡、发热和上呼吸道感染在加奈索酮组发生率至少10%且高于安慰剂组。
  • 严重不良事件:加奈索酮组6/50例(12%),安慰剂组5/51例(10%);因不良事件终止试验:加奈索酮组2/50例(4%),安慰剂组4/51例(8%);双盲阶段无死亡。

关键数值与推荐

  • 主要疗效终点为基线期至17周双盲阶段28天主要运动性发作频率中位数百分比变化,采用Wilcoxon秩和检验,在至少接受一剂试验治疗且有基线数据的患者中分析。
  • 安全性在至少接受一剂试验治疗的所有患者中描述性比较。
  • 主要运动性发作定义为双侧强直、全面强直-阵挛、双侧阵挛、失张力或局灶继发双侧强直-阵挛发作。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CDKL5 deficiency disorder (CDD) is a rare, X-linked, developmental and epileptic encephalopathy characterised by severe global developmental impairment and seizures that can begin in the first few months after birth and are often treatment refractory. Ganaxolone, an investigational neuroactive steroid, reduced seizure frequency in an open-label, phase 2 trial that included patients with CDD. We aimed to further assess the efficacy and safety of ganaxolone in patients with CDD-associated refractory epilepsy. METHODS: In the double-blind phase of this randomised, placebo-controlled, phase 3 trial, done at 39 outpatient clinics in eight countries (Australia, France, Israel, Italy, Poland, Russia, the UK, and the USA), patients were eligible if they were aged 2-21 years with a pathogenic or probably pathogenic CDKL5 variant and at least 16 major motor seizures (defined as bilateral tonic, generalised tonic-clonic, bilateral clonic, atonic, or focal to bilateral tonic-clonic) per 28 days in each 4-week period of an 8-week historical period. After a 6-week prospective baseline period, patients were randomly assigned (1:1) via an interactive web response system to receive either enteral adjunctive ganaxolone or matching enteral adjunctive placebo (maximum dose 63 mg/kg per day for patients weighing ≤28 kg or 1800 mg/day for patients weighing >28 kg) for 17 weeks. Patients, caregivers, investigators (including those analysing data), trial staff, and the sponsor (other than the investigational product manager) were masked to treatment allocation. The primary efficacy endpoint was percentage change in median 28-day major motor seizure frequency from the baseline period to the 17-week double-blind phase and was analysed (using a Wilcoxon-rank sum test) in all patients who received at least one dose of trial treatment and for whom baseline data were available. Safety (compared descriptively across groups) was analysed in all patients who received at least one dose of trial treatment. This study is registered with ClinicalTrials.gov, NCT03572933, and the open-label extension phase is ongoing. FINDINGS: Between June 25, 2018, and July 2, 2020, 114 patients were screened for eligibility, of whom 101 (median age 6 years [IQR 3 to 10]) were randomly assigned to receive either ganaxolone (n=50) or placebo (n=51). All patients received at least one dose of a study drug, but seizure frequency for one patient in the ganaxolone group was not recorded at baseline and so the primary endpoint was analysed in a population of 100 patients. There was a median percentage change in 28-day major motor seizure frequency of -30·7% (IQR -49·5 to -1·9) in the ganaxolone group and of -6·9% (-24·1 to 39·7) in the placebo group (p=0·0036). The Hodges-Lehmann estimate of median difference in responses to ganaxolone versus placebo was -27·1% (95% CI -47·9 to - 9·6). Treatment-emergent adverse events occurred in 43 (86%) of 50 patients in the ganaxolone group and in 45 (88%) of 51 patients in the placebo group. Somnolence, pyrexia, and upper respiratory tract infections occurred in at least 10% of patients in the ganaxolone group and more frequently than in the placebo group. Serious adverse events occurred in six (12%) patients in the ganaxolone group and in five (10%) patients in the placebo group. Two (4%) patients in the ganaxolone group and four (8%) patients in the placebo group discontinued the trial. There were no deaths in the double-blind phase. INTERPRETATION: Ganaxolone significantly reduced the frequency of CDD-associated seizures compared with placebo and was generally well tolerated. Results from what is, to our knowledge, the first controlled trial in CDD suggest a potential treatment benefit for ganaxolone. Long-term treatment is being assessed in the ongoing open-label extension phase of this trial. FUNDING: Marinus Pharmaceuticals.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Knight EMP, Amin S, Bahi-Buisson N, et al. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2022. PMID: 35429480. doi:10.1016/S1474-4422(22)00077-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。